熱門資訊> 正文

Ascendis Pharma在收购猜测中上涨

2026-01-23 00:47

Ascendis製藥(ASND) 0

Ascendis Pharma (ASND) gained 7.5% amid some takeover speculation.
There's talk that a Switzerland-based pharma company and another European firm are eyeing Ascendis (ASND), according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday.
Betaville first reported last month that the Danish pharmaceutical firm may have attracted takeover interest.
Ascendis (ASND) has a market cap of $13.3 billion.

More on Ascendis Pharma

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia - Slideshow
Ascendis dwarfism drug candidate review extended by FDA
Ascendis Pharma GAAP EPS of - €1.00, revenue of €213.63M

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。